Samsung Bioepis Partners With Teva on Biosimilars
Teva will handle U.S. sales of two Samsung Bioepis biosimilars under a contract worth up to 420 million dollars.
Updated on Nov. 3, 2026 in Biotech
Samsung Epis Holdings disclosed on November 3 that its subsidiary Samsung Bioepis signed an agreement with Teva Pharmaceuticals International for U.S. commercialization of two biosimilars. Samsung Bioepis will handle development, production and supply, while Teva will manage U.S. sales.
Why it matters
The contract size equals about 34% of Samsung Bioepis's consolidated sales last year, underscoring the deal's weight for the company. It also extends an existing collaboration in which the two companies already cooperate on U.S. sales of Episcli and Canadian sales of Opuviz.
The disclosed contract value of up to 420 million dollars equals roughly 34% of Samsung Bioepis's 2025 consolidated sales, with up to 75 million dollars paid upfront. Of that upfront amount, 25 million dollars remains contingent on conditions not yet specified.
The players
Samsung Bioepis
The biosimilar subsidiary of Samsung Epis Holdings, focused on developing and manufacturing biosimilar medicines.
Teva Pharmaceuticals International
The Swiss subsidiary of Teva Pharmaceuticals, a global generic and specialty drugmaker handling the U.S. commercialization.
The details
Under the agreement, Samsung Bioepis will develop, produce and supply Remsima (SB2), a biosimilar of Janssen's Remicade, and Eticovo (SB4), a biosimilar of Amgen's Enbrel, both already approved by the U.S. Food and Drug Administration. Teva will handle U.S. sales, and the deal is signed with Teva Pharmaceuticals International, its Swiss subsidiary.
Timeline
November 3: Samsung Epis Holdings discloses the partnership agreement.
Within 30 days of the contract's effective date: 50 million dollars of the upfront payment is scheduled to be received.
Biosimilar Partnerships
The agreement builds on Samsung Bioepis's existing U.S. sales arrangement with Teva for Episcli and its Canadian arrangement for Opuviz. It adds Remsima and Eticovo, extending a pattern in which a biosimilar developer pairs with an established Western distributor for market access.
For patients, the approvals mean Remsima and Eticovo are available as lower-cost alternatives to Remicade and Enbrel for treatment of Crohn's disease, rheumatoid arthritis and psoriasis, though pricing is not stated in the disclosure. Actual availability in U.S. pharmacies will depend on Teva's commercial rollout.
The takeaway
The deal shows how biosimilar makers are increasingly relying on established distributors to reach the U.S. market, a model that can shape which lower-cost alternatives reach patients. Watch for disclosure of the conditions attached to the remaining upfront payment and milestone progress.
Further reading
For broader context on the drug-development sector behind this deal, explore our Biotech coverage.
